A Chinese traditional medicine claiming to relieve all H1N1 swine flu symptom in two or three, especially in children has been launched in China, reports said.
The Chinese traditional medicine called “No 2 Cold Medicine” is capable of curing the H1N1 swine flu in a single dose treatment in most of the cases, the maker of the medicine was quoted as saying in local press.
“Some children will be cured with only one dose, while others might need two,” the company official has stated.
The Chinese traditional “No 2 Cold Medicine” is not only fast-acting but it safer also with no side-effects. “No 2 Cold Medicine” does not harm the stomach, unlike its western counterparts.
No 2 cold medicine is an upgrade of former anti-flu medicines.
However, experts said the medicine is basically the same as an ordinary Chinese anti-flu drug.
As the number of H1N1 cases crossed 6,200 in Beijing, 20 traditional Chinese medical hospitals opened 24-hour anti-H1N1 departments, the paper said.
The World Health Organization said it was not familiar with the traditional Chinese medicine recommended for children and could not comment, the Chinese daily said.
Currently, oseltamivir (Tamiflu) from Roche and zanamivir (Relenza) marketed by GlaxoSmithKline are the only two approved antiviral drugs that are available for treatment of the H1N1 swine flu virus.
About 50,000 confirmed H1N1 swine flu cases have been reported in China. Seven people have died of the disease and 118 are in critical condition.
China was the first country to complete tests of a swine flu vaccine and started the vaccination campaign in September.
China plans to produce up to 360 million doses of the vaccine, and proposes to allocate a total of $725 million on efforts to prevent the disease.
Last week, China’s Ministry of Industry and Information Technology ordered Sinovac Biotech Ltd an additional 5.19 million doses of Panflu.1 (15ug/0.5ml) for the Chinese central government stockpile.
Under this purchase order, Sinovac is required to produce an additional 5.19 million doses of Panflu.1 (15ug/0.5ml) for the Chinese central government.
Out of announced Panflu.1 order, Sinovac is required to complete delivery of 2.89 million doses to the appointed provincial and municipal governments by the end of this year and supply the remaining 2.3 million doses for the central government stockpiling.
The latest 5.19 million dose purchase order is in addition to an initial order for 3.3 million doses and second order for 3 million doses received by Sinovac from the Ministry of Industry and Information Technology of China on September 4, 2009 and September 30, 2009, respectively, for a total of 11.49 million doses.
Sinovac is a leading provider of biopharmaceutical products in China.
Sinovac also won the bidding process to supply its seasonal flu vaccine, Anflu, to the Shanghai government. The purchase plan from the Shanghai government reflected an expansion of government purchase programs for the seasonal flu vaccine. As part of the beneficial policies for citizens of Shanghai, certain Shanghai citizens will receive inoculation against influenza for free or with certain allowances.